Biol Stock is Up 20% in Pre-Market Trading
BIOLASE stock is up 20% in pre-market trading. The company is a leader in dental lasers and is looking to expand into new areas. It is trading at 47 cents a share and must be above $1 to stay on the Nasdaq. However, BIOLASE was recently granted an extension of 180 days to meet that requirement. This could help the company grow into a billion dollar company. But there is also risk involved.
While BIOLASE stock has made gains over the past several years, its long-term prospects are far more bleak. The company’s share price has fallen more than ninety percent over the past 15 years. If BIOLASE stock falls below $1 again, it will be removed from the Nasdaq and start trading on the pink sheets. The company will then need to come up with a plan to right the ship.
The current situation of BIOLASE’s stock is uncertain. The stock has been on a decline since its initial public offering in 1992. The company’s share price peaked at less than $100 per share 2004. Since then, it has been eroding, and it’s now trading at about $25 apiece. Nonetheless, it’s unlikely that the company will get that high again before it is removed from the Nasdaq. The company’s shares will likely trade in the “pink sheets,” meaning that they’ll be traded on a lower volume than if they were on the NASDAQ.
While BIOLASE’s stock has fallen steadily in recent years, the stock has remained above $1. The company’s shares have been falling for the last 15 years, and the recent Nasdaq listing has slowed the company’s slide. However, the extension should help the Foothill Ranch-based company gain confidence in its future and improve its financials. If the stock remains above $1, then it is a buy signal.
While BIOLASE stock is headed in the right direction, it is a volatile investment and can fall as low as $1. The company has a strong track record of falling shares, so it’s important to keep an eye on this stock. If it can get its share price above $1, it can make a strong case for recovery. However, it’s important to note that BIOLASE will need to improve its financials and gain confidence of investors to avoid further declines.
BIOLASE stock has fallen steadily since its initial public listing in 1992. Its shares reached a high of nearly $100 in 2004 and have remained below that level for the last 15 years. After a Nasdaq extension, the stock may be delisted from the Nasdaq. It could be forced to trade on the over-
the-counter market, also known as the pink sheets. This can impact the liquidity of BIOLASE’s share price.
BIOLASE stock has been on the rise over the past several years. However, it has been falling steadily since March 17, 2022. Its shares have dropped by 9.59%. But, it did make a low-priced bottom pivot in the last few days. Its last day’s volume has increased. This is a warning sign that BIOLASE will soon be slipping. Despite its high-priced share, it still has to prove its worth to remain on Nasdaq.
If BIOLASE stock falls below $1, it will be removed from the Nasdaq. In the long run, the stock’s price will likely fall below the $1 level. If the company manages to stay on the Nasdaq, BIOLASE stock will continue to rise. Its new price may be supported by the stock’s declining volume. If the company can keep its momentum, the stock will move higher. In the near term, BIOLASE shares could reach a high of $8.73 a.
BIOLASE stock has been declining for several years. In 2004, it peaked at under $100 a share. In March, the company continued to decline until it hit a new low pivot. It was also gaining volume on its last day. This is a positive sign. In general, increasing volume on a falling stock can signal a bullish trend. Therefore, BIOLASE shares should rise to at least $1 in the near future.